Premium
Circumvention of multi‐drug resistance in human kidney and kidney carcinoma in vitro
Author(s) -
Volm Manfred,
Pommerenke Elke W.,
Efferth Thomas,
Löhrke Heinz,
Mattern Jürgen
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910515)67:10<2484::aid-cncr2820671016>3.0.co;2-i
Subject(s) - trifluoperazine , doxorubicin , kidney , medicine , immunocytochemistry , p glycoprotein , pharmacology , drug resistance , calmodulin , cancer research , multiple drug resistance , pathology , biology , chemotherapy , calcium , microbiology and biotechnology
This report investigated whether the calmodulin inhibitor, trifluoperazine, can circumvent multi‐drug resistance both in primary tissue cultures of human kidney and kidney carcinoma. For detection of inherent multi‐drug resistance, the expression of P‐glycoprotein was determined by immunofluorescence and immunocytochemistry using the monoclonal antibody C219. For detection of doxorubicin resistance and reversal of this resistance by trifluoperazine, the incorporation of nucleic acid precursor was measured after addition of doxorubicin and trifluoperazine, respectively. Both P‐glycoprotein expressing resistant normal and malignant kidney tissue cultures could be modified by trifluoperazine. However, sensitive normal kidney and kidney carcinoma cultures were little affected by trifluoperazine. Thus, circumvention of primary resistance to doxorubicin is not limited to tumor cells. This might have important implications for the use of resistance modifiers in the clinical setting.